Relevium Secures CBD Supply Agreement for European Market

Relevium Technologies Inc. (TSX-V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce it has executed a supply agreement with Plena Global Holdings Inc., a Canadian based holding company accumulating medical marijuana grow production assets across legalized countries in South America, to supply full spectrum CBD oil to Relevium’s supply chain partners in Europe starting January 2019.

Highlights

• Relevium is currently expanding its brand reach into the European Market
• Exclusive CBD infused nutraceutical formulations are at the core of the ongoing plans for the European Market
• Delivery of full spectrum CBD oil will begin in January of 2019
• Relevium has already defined an initial product line and is in the process of finalizing formulations of its first CBD based nutraceuticals for the European Market

The Company is leveraging its current market expansion initiatives into the European Marketplace to accelerate the introduction of Cannabinoid based nutraceutical supplements in this lucrative and accessible market. In order to secure high quality supply of full spectrum CBD oil directly to its European supply chain partners, the Company has signed an agreement with Plena Global Holdings, a company with 130 million square feet of committed grow operations that meet Canadian and European standards.

Aurelio Useche CEO Stated: “Our supply partnership with Plena Global Holdings is a critical milestone for Relevium as it ensures a steady long-term supply of superior quality full spectrum CBD oil for the company’s nutraceutical retail brands currently being launched in Europe”.

About Plena Global

Plena Global Holdings Inc. is a holding company based in Canada accumulating medical marijuana grow production assets across legalized countries in South America. Plena is focused on developing large-scale production of GMP grade medical marijuana products for export to countries with supply shortages, such as Canada, Germany and Italy. Plena brings together some of the world’s top cannabis scientists, growers, extraction specialists, and medical leaders, to develop and deliver the highest quality medical marijuana supplies to the world.

About Relevium Technologies

Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or brands with a focus on e-commerce in the growing health and wellness sector. The Company, through its wholly-owned subsidiary, Biocannabix Health Corporation, is also incorporating cannabinoids into its nutraceutical strategy and provide its retail customers access to the health benefits of cannabis through its formulations and established brands.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.